Senseonics (SENS) Competitors

EyePoint Pharmaceuticals (NASDAQ:EYPT) and Senseonics (NYSE:SENS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, community ranking, analyst recommendations and dividends.

Is EYPT or SENS more profitable?

EyePoint Pharmaceuticals has a net margin of -226.57% compared to Senseonics' net margin of -362.30%. EyePoint Pharmaceuticals' return on equity of -43.01% beat Senseonics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
EyePoint Pharmaceuticals	-226.57%	-43.01%	-31.63%
Senseonics	-362.30%	-842.25%	-67.99%

Which has higher earnings and valuation, EYPT or SENS?

Senseonics has lower revenue, but higher earnings than EyePoint Pharmaceuticals. EyePoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Senseonics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EyePoint Pharmaceuticals	$46.02M	13.28	-$70.79M	-$2.00	-4.48
Senseonics	$22.21M	8.61	-$60.39M	-$0.13	-2.48

Do insiders and institutionals hold more shares of EYPT or SENS?

99.4% of EyePoint Pharmaceuticals shares are held by institutional investors. Comparatively, 12.4% of Senseonics shares are held by institutional investors. 4.7% of EyePoint Pharmaceuticals shares are held by company insiders. Comparatively, 3.9% of Senseonics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has more volatility & risk, EYPT or SENS?

EyePoint Pharmaceuticals has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Senseonics has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.

Do analysts rate EYPT or SENS?

EyePoint Pharmaceuticals presently has a consensus target price of $28.00, suggesting a potential upside of 212.67%. Senseonics has a consensus target price of $2.00, suggesting a potential upside of 519.77%. Given Senseonics' higher possible upside, analysts clearly believe Senseonics is more favorable than EyePoint Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EyePoint Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00
Senseonics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor EYPT or SENS?

In the previous week, EyePoint Pharmaceuticals had 3 more articles in the media than Senseonics. MarketBeat recorded 8 mentions for EyePoint Pharmaceuticals and 5 mentions for Senseonics. Senseonics' average media sentiment score of 0.27 beat EyePoint Pharmaceuticals' score of 0.15 indicating that Senseonics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
EyePoint Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Senseonics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community prefer EYPT or SENS?

EyePoint Pharmaceuticals received 460 more outperform votes than Senseonics when rated by MarketBeat users. Likewise, 70.15% of users gave EyePoint Pharmaceuticals an outperform vote while only 9.68% of users gave Senseonics an outperform vote.

Company	Underperform	Outperform
EyePoint Pharmaceuticals	Outperform Votes 463 70.15%	Underperform Votes 197 29.85%
Senseonics	Outperform Votes 3 9.68%	Underperform Votes 28 90.32%

Summary

EyePoint Pharmaceuticals beats Senseonics on 12 of the 17 factors compared between the two stocks.